Case Report

Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era

Dimitrios Farmakiotis, Zoe Weiss, Amy L. Brotherton, Paul Morrissey, Reginald Gohh, Kendra Vieira, Lynn E. Taylor, and Joseph M. Garland

Division of Infectious Diseases, Department of Internal Medicine, Brown Alpert Medical School, Providence, RI, USA
Department of Internal Medicine, Brown Alpert Medical School, Providence, RI, USA
Division of Infectious Diseases, Brigham and Women’s Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Department of Pharmacy, The Miriam Hospital, Providence, RI, USA
Division of Nephrology (Transplantation), Department of Internal Medicine, Brown Alpert Medical School, Providence, RI, USA
CODAC Behavioral Health, Providence, RI, USA

Correspondence should be addressed to Dimitrios Farmakiotis; dimitrios.farmakiotis@lifespan.org

Received 23 September 2019; Accepted 3 January 2020; Published 30 January 2020

1. Background

Contemporary cohorts of HIV-infected transplant recipients have demonstrated excellent patient and graft survival [1–7]. Similarly, for patients with hepatitis C virus (HCV) infection, kidney transplantation offers a survival benefit and can be more cost-effective than remaining on the waitlist [8–10]. However, compared to their HCV-uninfected counterparts, these patients experience higher rates of post-transplant glomerulonephritis, malignancy, and progression of liver disease [11, 12].

Historically, HCV eradication was a challenge in transplanted patients, as interferon-containing regimens were relatively contraindicated due to increased risk of rejection [13]. The introduction of direct-acting antivirals (DAA) allows for safe treatment of HCV-infected transplant recipients, and therefore, transplantation of HCV-infected organs to both HCV-infected and uninfected patients
[9, 14–19]. The optimal timing for treatment of HCV-infected transplant candidates (pre- vs. post-transplant with HCV-infected or HCV-uninfected organ donation, respectively) remains controversial, as the risk of treatment delay must be balanced by the benefit of shorter wait time for HCV-infected organs [7, 10, 13]. DAA prophylaxis for uninfected recipients of HCV-infected organs, including shorter courses [17], has also been proposed as an effective way to expand the organ pool [16–18].

Given similar routes of transmission, coinfection with hepatitis B virus (HBV) or HCV is common among HIV-infected patients with end-stage renal disease (ESRD) [5]. Higher overall morbidity, mortality, and accelerated hepatic decompensation have been observed in this population, compared to HIV monoinfected patients [20, 21], likely due to the immune modulating effects of HCV [22], including activation of CD4+ and CD8+ cells [23] and cytokine production [24]. In the pre-DAA era, transplantation in patients coinfected with HIV and HCV was associated with reduced graft survival and higher rates of serious infection [25]. However, recent small case series showed improved outcomes, including fewer infectious complications, in coinfected patients treated with DAA after transplant [3, 4, 6].

Despite significant advances in transplantation of HIV/HCV coinfected individuals, little is known about coinfected patients with HCV genotypes other than genotype 1, especially when receiving HCV-positive organs with a different genotype. Herein, we describe the first case of kidney transplantation in a man coinfected with hepatitis C and HIV in the State of Rhode Island. To our knowledge, this is also the first reported case of discordant HCV genotype transplantation in a patient coinfected with HIV, in the DAA era.

2. Case Report

A 64-year-old man with ESRD from diabetic nephropathy on hemodialysis for one year presented for transplant evaluation. He had a remote history of polysubstance addiction including heroin injection with methadone detoxification and then complete nonuse of illicit drugs for decades; he did not want opioid agonist therapy and was on hemodialysis for one year presented for transplant evaluation. He had a remote history of polysubstance addiction and then complete nonuse of illicit drugs for decades; he did not want opioid agonist therapy and was on hemodialysis for one year presented for transplant evaluation.

He had a history of well-controlled HIV diagnosed in 1987, with an undetectable viral load and CD4-infected cell count > 500 cells/mm³ for many years. He had been on numerous prior antiretroviral regimens to treat his HIV and harbored multiclass resistance to agents in the non-nucleoside reverse transcriptase inhibitor (NRTI: M184V and T215N/S/Y) and protease inhibitor (PI: L33I, M46I, I54V, I62V, and V82A/I/T) classes. He ultimately achieved long-term virologic suppression with etravirine, darunavir, ritonavir, and raltegravir (the TRIO [26, 27] regimen). In advance of transplant, his resistance history was reviewed and an HIV-1 proviral DNA genotype archive was sent, which did not demonstrate any resistance to the integrase inhibitor or the NNRTI class. He was switched to rilpivirine and dolutegravir [28] to reduce the risk of drug-drug interactions (DDI) (ritonavir significantly increases calcineurin inhibitor (CNI) levels) and to avoid complex dose adjustment with fluctuating renal function post-transplant.

The patient was also infected with HBV. Tenofovir disoproxil fumarate had been discontinued several years before due to concern for contribution to his progressive renal disease, and he was maintained on lifelong entecavir treatment. He also had chronic hepatitis C virus (HCV), genotype 2b, and declined interferon therapy for years. By the time DAAAs became available, there was no DAA for genotype 2 that could be given with his degree of advanced renal disease. When he developed advanced fibrosis (F3), it was recommended that consideration of renal transplant be accelerated given advancing liver disease. He had a history of coronary artery disease (CAD) and inferior myocardial infarction eight years before, with a stent placed to the right coronary artery (RCA). He was taking aspirin 325 mg daily and atorvastatin 40 mg daily. As part of his pretransplant evaluation, a nuclear myocardial perfusion test revealed a large-sized inferior and inferolateral fixed defect with preserved ejection fraction. The patient had very good functional status and did not report any symptoms, so further preoperative cardiac workup was not pursued.

Three months after listing, he underwent deceased donor kidney transplant from an HCV-positive donor (by antibody and nucleic acid-testing (NAT)-genotype 1a) with basiliximab induction. Maintenance immunosuppression included mycophenolate sodium, tacrolimus, and prednisone. He was also started on valganciclovir and atovaquone prophylaxis due to sulfonamide allergy. On postoperative day (POD) 1, he developed substernal anginal chest pain. An electrocardiogram (EKG) showed ST depressions in the anterolateral leads and transient ST elevation in lead III (Figure 1). His serum troponin peaked at 31 ng/ml (normal <0.06 ng/ml). He was treated with aspirin, clopidogrel, and nitroglycerin drip, without anticoagulation, for fear of hemorrhage due to extensive retroperitoneal blunt dissection during transplant. He underwent cardiac catherization on POD3, which revealed 3-vessel disease, with near-complete occlusion of the RCA stent (Figure 2(a)). On POD 10, he had successful placement of two drug-eluting stents in the RCA (Figure 2(b)). The patient experienced delayed graft function, requiring hemodialysis but was eventually discharged off dialysis on POD 15. Of note, on POD 9 his HCV genotype was 2b, but subsequent genotype before initiation of treatment (POD 81) was only 1a (donor-derived). On POD 100, the patient was admitted for febrile neutropenia, requiring colony-stimulating growth factor support and discontinuation of both valganciclovir and mycophenolate.

On POD 141, he was started on therapy for HCV, with pangenotypic glecaprevir/pibrentasvir (GLE/PIB) for 12 weeks, targeting both donor and recipient genotypes. Concomitant use of GLE/PIB and atorvastatin is contraindicated; thus, he was switched to pravastatin during treatment. Additionally, therapeutic drug monitoring of...
tacrolimus levels was increased to twice weekly for the first month and weekly for the next 2 months, before resuming laboratory workup per transplant protocol (twice every month until 6 months after transplant, then monthly). He required transient reduction of his tacrolimus dose from 2 mg to 1 mg twice daily (bid) because of supratherapeutic trough levels (highest: 18 mg/dL, post-transplant goal: 7 mg/dL), one week after starting GLE/PIB. After 3 weeks, the tacrolimus dose was again increased to 2 mg bid (Figure 3). He achieved sustained virologic response (SVR) 12 weeks after treatment completion (SVR 12). He developed high-level BK viremia 1.5 year after transplant, which resolved by decreasing the tacrolimus trough goal to 4 mg/dL. Two years after transplant, he is doing well, and has excellent graft function and undetectable HIV, HCV, and HBV viral loads. He remains on entecavir prophylaxis.

3. Discussion

Management of patients with HIV and HCV/HBV tri-infection in the setting of ESRD presents unique challenges, including increased cardiovascular mortality, rapid progression of end organ dysfunction, infections, and DDI. Moreover, the rapidly changing landscape of HCV management in the DAA era has important implications for organ allocation. To our knowledge, this is the first report of an HIV/HCV/HBV coinfected patient with the non-1 HCV genotype who received an HCV-infected organ transplant with the discordant genotype. The lessons learnt are of clinical significance.

Cardiovascular disease and rates of myocardial infarction are already increased in patients with ESRD [29], but possibly further potentiated by HIV/HCV coinfection [30],
by way of chronic inflammation, endothelial dysfunction, metabolic derangements [30–34], and potential choice of antiretroviral therapy [35]. Assessing cardiovascular risk in the pretransplant evaluation is imperative. Given the burden of cardiovascular disease in the ESRD population and frequent lack of symptoms, noninvasive cardiac imaging might be inferior to cardiac catheterization. In one study of kidney transplant candidates with cardiovascular risk factors other than HIV/HCV, the positive and negative predictive values of noninvasive means in detecting clinically significant cardiovascular disease were only 43% and 47%, respectively. Furthermore, mortality was reduced in those who underwent elective revascularization pretransplantation [29]. At our institution, following this case, we have a very low threshold for coronary angiography in HIV-infected or HCV-infected transplant candidates with a history of significant CAD, regardless of reported symptoms.

Management of DDI in patients coinfected with HIV and HCV is paramount, even more so in the setting of organ transplantation [3–5, 7, 13]. Fewer DDI are probably one of the main factors responsible for improved outcomes with InSTI compared to PI after organ transplantation in patients with HIV [4]. Coadministration of GLE/PIB with systemic tacrolimus (1 mg single dose) has been shown to increase tacrolimus $C_{\text{max}}$ and area under the curve (AUC) by 1.5-fold and 1.45-fold, respectively. There was no change in the $C_{\text{min}}$ AUC, and $C_{\text{min}}$ of GLE or PIB [36]. As tacrolimus has a narrow therapeutic index, the official recommendation is to use with caution and with therapeutic drug monitoring, but without a priori dose adjustment. In general, improved liver function with anti-HCV treatment may further contribute to increased clearance of tacrolimus. In agreement with the above, our patient experienced an increase in tacrolimus trough level with initiation of GLE/PIB, resulting in dose reduction and subsequently decreased levels. Therefore, during coadministration of GLE/PIB and tacrolimus, we favor checking tacrolimus trough levels initially twice weekly and then weekly for the duration of treatment and a few weeks after, before resuming our regular per protocol laboratory workup.

In the setting of donor and recipient genotype strain mismatch, both viral strains may exist in the perioperative period. However, over the first few months post-transplantation, one strain will generally predominate although long-term detection of both genotypes is possible [19, 37, 38]. Recommended regimens for the treatment of HCV in kidney transplant recipients include ledipasvir/sofosbuvir, velpatasvir/sofosbuvir, and GLE/PIB. All are active against the most frequent genotype (1), and velpatasvir/sofosbuvir and GLE/PIB are pangenotypic and should be preferred in transplant recipients with donor/recipient genotype mismatch. It should be noted that strains with genotype 1 are likely more dominant (1b > 1a > 2), based on limited data, which is mostly derived from liver transplant recipients [37, 38]. This was confirmed in our case, despite kidney, not liver, transplantation, and therefore, substantially lower donor genotype 1a, compared to recipient genotype 2, viral load burden.

The optimal timing of DAA treatment in HCV-positive transplant candidates, including HIV coinfected patients, remains in a state of flux, with limited real-world data [7, 9, 10]. The risk of treatment delay and progression of liver disease, which can be accelerated by immunosuppression, should be weighed against the benefit of shorter wait time for HCV-infected organs. Based on sophisticated modelling, it has been suggested that for HCV-monoinfected patients with minimal liver fibrosis, treatment post-transplantation with an HCV-positive organ is beneficial. Nevertheless, in patients with advanced fibrosis, treatment prior to transplant may be preferred, unless the wait time benefit is >9 months [10]. For HCV/HIV coinfected patients, treatment post-transplant was consistently cost-saving as compared to treatment pretransplant and associated with higher life months and quality-adjusted life months with wait times.
Case Reports in Hepatology 5

>18 months [7]. At the time of our case, the wait time within our organ procurement organization (OPO) was <6 months vs. >4 years for HCV-positive vs. negative deceased donors, respectively. Thus, despite our patient’s advanced stage of fibrosis, the decision to wait was justified.

In summary, our case study highlights the following: (1) transplant centers need to monitor OPO-specific times on the waitlist for an HCV-infected organ and to assess regularly the risk of delaying treatment for HCV-infected transplant candidates in anticipation of transplant from an HCV-infected donor; (2) closer monitoring of tacrolimus levels (once or twice weekly) during the early phases of anti-HCV PI introduction and discontinuation may be indicated; (3) the possibility of donor genotype transmission makes the use of pan-genotypic DAA post-transplant appealing as the standard of care; (4) HIV/HCV coinfected transplant candidates require a holistic approach with emphasis on the cardiovascular risk profile and low threshold for cardiac catheterization as part of their pretransplant evaluation.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

DF has received research support from Astellas and Viracor-Eurofins and consultant fee from Viracor-Eurofins. The present work was supported by a Brown Physicians Inc. Academic Assessment Grant.

References

[1] J. E. Locke, R. D. Reed, S. G. Mehta et al., "Center-level experience and kidney transplant outcomes in HIV-infected recipients," American Journal of Transplantation, vol. 15, no. 8, pp. 2096–2104, 2015.

[2] P. G. Stock, B. Barin, B. Murphy et al., "Outcomes of kidney transplantation in HIV-infected recipients," New England Journal of Medicine, vol. 363, no. 21, pp. 2004–2014, 2010.

[3] J. F. Camargo, S. Anjan, and N. Chin-Beckford, "Clinical outcomes in HIV-infected/HCV-infected coinfection kidney transplant recipients in the pre- and post-direct-acting antiviral therapy era: 10-year single center experience," Clinical Transplantation, vol. 33, no. 5, Article ID e13532, 2019.

[4] R. Rosa, J. F. Suarez, M. A. Lorio et al., "Impact of antiretroviral therapy on clinical outcomes in HIV (-infected) kidney transplant recipients: review of 58 cases," F1000Research, vol. 5, p. 2893, 2016.

[5] D. Sawinski, “ESRD patients coinfected with human immunodeficiency virus and hepatitis C: outcomes and management challenges,” Seminars in Dialysis, vol. 32, no. 2, pp. 159–168, 2019.

[6] D. Sawinski, D. H. Lee, A. M. Doyle, and E. A. Blumberg, "Successful posttransplant treatment of hepatitis C with ledipasvir-sofosbuvir in HIV-infected kidney transplant recipients," Transplantation, vol. 101, no. 5, pp. 974–979, 2017.

[7] B. A. Shelton, G. Berdahl, D. Sawinski et al., "Optimal timing of hepatitis C treatment among HIV/HCV coinfected ESRD patients: pre- vs posttransplant," American Journal of Transplantation, vol. 19, no. 6, pp. 1806–1819, 2019.

[8] D. Roth, J. J. Gaynor, K. R. Reddy et al., “Effect of kidney transplantation on outcomes among patients with hepatitis C,” Journal of the American Society of Nephrology, vol. 22, no. 6, pp. 1152–1160, 2011.

[9] D. Sawinski, N. Patel, B. Appolo, and R. Bloom, "Use of HCV-infected Donors does not affect HCV clearance with directly acting antiviral therapy but shortens the wait time to kidney transplantation," Transplantation, vol. 101, no. 5, pp. 968–973, 2017.

[10] B. A. Shelton, D. Sawinski, B. P. Linas et al., “Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation,” American Journal of Transplantation, vol. 18, no. 10, pp. 2483–2495, 2018.

[11] V. Saxena and N. A. Terrault, "Treatment of hepatitis C infection in renal transplant recipients: the long wait is over," American Journal of Transplantation, vol. 16, no. 5, pp. 1345–1347, 2016.

[12] S. Belga and K. E. Doucette, "Hepatitis C in non-hepatic solid organ transplant candidates and recipients: a new horizon," World Journal of Gastroenterology, vol. 22, no. 4, pp. 1650–1663, 2016.

[13] D. Sawinski and R. D. Bloom, “Novel hepatitis C treatment and the impact on kidney transplantation,” Transplantation, vol. 99, no. 12, pp. 2458–2466, 2015.

[14] M. Lubetzky, S. Chun, A. Joelson et al., “Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents,” Transplantation, vol. 101, no. 7, pp. 1704–1710, 2017.

[15] D. S. Goldberg, P. L. Abt, E. A. Blumberg et al., "Trial of transplantation of HCV-infected kidneys into uninfected recipients," New England Journal of Medicine, vol. 376, no. 24, pp. 2394–2395, 2017.

[16] C. M. Durand, M. G. Bowring, D. M. Brown et al., “Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial,” Annals of Internal Medicine, vol. 168, no. 8, pp. 533–540, 2018.

[17] A. E. Woolley, S. K. Singh, H. J. Goldberg et al., “Heart and lung transplants from HCV-infected donors to uninfected recipients,” New England Journal of Medicine, vol. 380, no. 17, pp. 1606–1617, 2019.

[18] A. Abdelbasit, A. Hirji, K. Halloran et al., “Lung transplantation from hepatitis C viremic donors to uninfected recipients,” American Journal of Respiratory and Critical Care Medicine, vol. 197, no. 11, pp. 1492–1496, 2018.

[19] J. Levitsky, R. N. Formica, R. D. Bloom et al., “Iatrogenic infection from hepatitis C viremic donors to uninfected recipients,” American Journal of Transplantation, vol. 16, no. 5, pp. 1663, 2016.

[20] A. E. Woolley, S. K. Singh, H. J. Goldberg et al., “Heart and lung transplants from HCV-infected donors to uninfected recipients,” New England Journal of Medicine, vol. 380, no. 17, pp. 1606–1617, 2019.

[21] J. Levitsky, R. N. Formica, R. D. Bloom et al., “The American society of transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation,” American Journal of Transplantation, vol. 17, no. 11, pp. 2790–2802, 2017.

[22] E. A. Operalski and A. Kovacs, “HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies,” Current HIV/AIDS Reports, vol. 8, no. 1, pp. 12–22, 2011.

[23] H.-H. Thein, Q. Yi, G. J. Dore, and M. D. Krahn, “Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis,” AIDS, vol. 22, no. 15, pp. 1979–1991, 2008.

[24] C. Körner, B. Krämer, D. Schulte et al., “Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients,” Clinical Science, vol. 116, no. 12, pp. 861–870, 2009.

[25] V. D. Gonzalez, K. Falconer, K. G. Blom et al., “High levels of chronic immune activation in the T-cell compartments of
patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment,” *Journal of Virology*, vol. 83, no. 21, pp. 11407–11411, 2009.

[24] A. Y. Kim and R. T. Chung, “Coinfection with HIV-1 and HCV-A one-two punch,” *Gastroenterology*, vol. 137, no. 3, pp. 795–814, 2009.

[25] Y. Xia, P. Friedmann, H. Yaffe, J. Phair, A. Gupta, and L. K. Kayler, “Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses,” *American Journal of Transplantation*, vol. 14, no. 9, pp. 2037–2047, 2014.

[26] C. Fagard, C. Colin, C. Charpentier et al., “Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial,” *JAIDS Journal of Acquired Immune Deficiency Syndromes*, vol. 59, no. 5, pp. 489–493, 2012.

[27] Y. Yazdanpanah, C. Fagard, D. Descamps et al., “High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial,” *Clinical Infectious Diseases*, vol. 49, no. 9, pp. 1441–1449, 2009.

[28] J. M. Llibre, C.-C. Hung, C. Brinson et al., “Efficacy, safety, and tolerability of dolutegravir-rlpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies,” *The Lancet*, vol. 391, no. 10123, pp. 839–849, 2018.

[29] D. M. Mann, S. Fernandez, Z. Mondal et al., “Role of coronary angiography in the assessment of cardiovascular risk in kidney transplant candidates,” *The American Journal of Cardiology*, vol. 118, no. 5, pp. 679–683, 2016.

[30] R. Bedimo, A. O. Westfall, M. Mugavero, H. Drechsler, N. Khanna, and M. Saag, “Hepatitis C virus co-infection and the risk of cardiovascular disease among HIV-infected patients,” *HIV Medicine*, vol. 11, no. 11, pp. 462–468, 2010.

[31] I. F. de Castro, D. Micheloud, J. Berenguer et al., “Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients,” *AIDS*, vol. 24, no. 13, pp. 2059–2067, 2010.

[32] O. Osibogun, O. Ogunmoroti, E. D. Michos et al., “HIV/HCV coinfection and the risk of cardiovascular disease: a meta-analysis,” *Journal of Viral Hepatitis*, vol. 24, no. 11, pp. 998–1004, 2017.

[33] J. V. Fernández-Montero, P. Barreiro, C. de Mendoza, P. Labarga, and V. Soriano, “Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients,” *Journal of Viral Hepatitis*, vol. 23, no. 1, pp. 47–52, 2016.

[34] L. Kakinami, R. C. Block, M. J. Adams, S. E. Cohn, B. Maliakkal, and S. G. Fisher, “Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population,” *International Journal of Clinical Practice*, vol. 67, no. 1, pp. 6–13, 2013.

[35] L. Ryom, J. D. Lundgren, W. El-Sadr et al., “Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study,” *The Lancet HIV*, vol. 5, no. 6, pp. e291–e300, 2018.

[36] M. P. Kosloski, W. Zhao, H. Li et al., “Drug-drug interactions of tacrolimus or cyclosporine with glecaprevir and pibrentasvir in healthy subjects,” *Clinical Pharmacology in Drug Development*, vol. 8, no. 6, pp. 779–789, 2019.

[37] X. Fan, D. M. Lang, Y. Xu et al., “Liver transplantation with hepatitis C virus-infected graft: interaction between donor and recipient viral strains,” *Hepatology*, vol. 38, no. 1, pp. 25–33, 2003.

[38] T. Laskus, L.-F. Wang, J. Rakela et al., “Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors,” *Virology*, vol. 220, no. 1, pp. 171–176, 1996.